Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Asston Pharmaceu
Quarter-by-quarter operating performance
Financials of Asston Pharmaceu
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 9.60 | 6.54 | 16.03 | 25.04 | 25.47 |
| Expenses + | 9.96 | 5.02 | 12.21 | 19.60 | 26.04 |
| Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.57 |
| OPM % | -3.75% | 23.24% | 23.83% | 21.73% | -2.24% |
| Other Income + | 0.96 | 0.65 | 0.25 | 0.57 | 6.12 |
| Interest | 0.43 | 0.72 | 0.76 | 0.95 | 0.63 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.04 | 0.32 |
| Profit before tax | 0.16 | 1.41 | 3.25 | 5.02 | 4.60 |
| Tax % | 31.25% | 25.53% | 25.23% | 23.11% | 15.87% |
| Net Profit + | 0.11 | 1.06 | 2.43 | 3.85 | 3.87 |
| EPS in Rs | 1.57 | 15.14 | 31.00 | 6.14 | 4.55 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Asston Pharmaceu
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.40 | 4.76 | 30.35 |
| Borrowings + | 3.31 | 5.24 | 6.82 | 7.25 | 5.11 |
| Other Liabilities + | 5.25 | 6.46 | 6.70 | 9.84 | 7.68 |
| Total Liabilities | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
| Fixed Assets + | 0.92 | 1.13 | 0.97 | 0.96 | 10.69 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 8.57 | 12.56 | 19.73 | 27.16 | 40.96 |
| Total Assets | 9.49 | 13.69 | 20.70 | 28.12 | 51.65 |
Financials of Asston Pharmaceu
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -1.19 | -0.32 | -3.97 | -0.03 | |
| Cash from Investing Activity + | 0.00 | -0.91 | -0.01 | 0.73 | |
| Cash from Financing Activity + | 1.29 | 1.21 | 3.86 | -0.51 | |
| Net Cash Flow | 0.10 | -0.01 | -0.12 | 0.19 | |
| Free Cash Flow | -1.19 | -0.57 | -3.98 | -0.06 | |
| CFO/OP | 322% | -20% | -92% | -0% |
Financials of Asston Pharmaceu
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 243.33 | 480.53 | 380.71 | 357.86 | 524.07 |
| Inventory Days | 27.24 | 204.29 | 53.91 | 18.59 | 16.14 |
| Days Payable | 246.78 | 754.51 | 217.50 | 154.11 | 120.76 |
| Cash Conversion Cycle | 23.79 | -69.70 | 217.12 | 222.34 | 419.45 |
| Working Capital Days | -12.17 | 43.53 | 162.80 | 178.86 | 434.22 |
| ROCE % | 37.14% | 37.78% | 36.62% | 16.80% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…